John Martin Insider Trading for 50,000 Shares of Gilead Sciences, Inc. (GILD); Credit Suisse Ag Decreased By $698,958 Its Banco Macro Sa (BMA) Holding

Credit Suisse Ag decreased Banco Macro Sa (BMA) stake by 44.07% reported in 2017Q3 SEC filing. Credit Suisse Ag sold 5,974 shares as Banco Macro Sa (BMA)’s stock rose 7.03%. The Credit Suisse Ag holds 7,581 shares with $889,000 value, down from 13,555 last quarter. Banco Macro Sa now has $8.05B valuation. The stock decreased 2.55% or $2.96 during the last trading session, reaching $113.12. About 264,507 shares traded. Banco Macro S.A. (NYSE:BMA) has risen 43.80% since January 9, 2017 and is uptrending. It has outperformed by 27.10% the S&P500.

Gilead Sciences Inc’s Executive Chairman, John Martin, made a sale of 50,000 shares of stock in the ‘s company. The documented cost for each share was $73.6, for total deal worth of $3,681,235 U.S. Dollars. He also unloaded 73,333 shares with a total value $5,498,385 USD in the last month. The regulatory filing shows that John Martin now has about 0.23% of the California-based company’s total market capitalization The deal was made public in a SEC filing on 04/01/2018.

Investors sentiment increased to 1.03 in 2017 Q3. Its up 0.10, from 0.93 in 2017Q2. It increased, as 96 investors sold Gilead Sciences, Inc. shares while 488 reduced holdings. 127 funds opened positions while 474 raised stakes. 957.62 million shares or 2.06% more from 938.32 million shares in 2017Q2 were reported. Commonwealth Fincl Bank Of Aus holds 0.22% of its portfolio in Gilead Sciences, Inc. (NASDAQ:GILD) for 284,030 shares. Lakeview Capital Limited Com invested 0.29% in Gilead Sciences, Inc. (NASDAQ:GILD). Moors & Cabot invested in 27,479 shares. Northwest Counselors Ltd Llc reported 814 shares. Raymond James Serv Advsr reported 0.15% stake. 50,530 are held by Lipe Dalton. Sentry Investments Corp owns 935,400 shares. Nexus Inv Mgmt, a Ontario – Canada-based fund reported 258,416 shares. Highlander Capital Mngmt Ltd Liability Company reported 0.08% in Gilead Sciences, Inc. (NASDAQ:GILD). Suntrust Banks Inc accumulated 265,395 shares. Parnassus Invs Ca holds 18.70 million shares. Johnson Group accumulated 37,861 shares. Seizert Prtn Llc invested in 592,989 shares or 1.76% of the stock. Da Davidson has invested 0.15% in Gilead Sciences, Inc. (NASDAQ:GILD). Blume Cap Mngmt has 4,700 shares.

Analysts await Gilead Sciences, Inc. (NASDAQ:GILD) to report earnings on February, 6. They expect $1.67 earnings per share, down 36.74% or $0.97 from last year’s $2.64 per share. GILD’s profit will be $2.18 billion for 11.14 P/E if the $1.67 EPS becomes a reality. After $2.23 actual earnings per share reported by Gilead Sciences, Inc. for the previous quarter, Wall Street now forecasts -25.11% negative EPS growth.

Among 30 analysts covering Gilead Sciences (NASDAQ:GILD), 18 have Buy rating, 0 Sell and 12 Hold. Therefore 60% are positive. Gilead Sciences has $137 highest and $7200 lowest target. $97.04’s average target is 30.43% above currents $74.4 stock price. Gilead Sciences had 111 analyst reports since July 29, 2015 according to SRatingsIntel. The firm has “Hold” rating given on Thursday, July 27 by Maxim Group. The rating was initiated by Oppenheimer on Thursday, February 11 with “Outperform”. The rating was maintained by Cowen & Co on Tuesday, May 30 with “Buy”. The company was maintained on Tuesday, May 30 by Maxim Group. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Buy” rating by Jefferies on Tuesday, September 6. Jefferies maintained Gilead Sciences, Inc. (NASDAQ:GILD) on Wednesday, August 31 with “Hold” rating. The firm has “Buy” rating given on Thursday, September 22 by Berenberg. The stock of Gilead Sciences, Inc. (NASDAQ:GILD) earned “Hold” rating by Needham on Tuesday, July 26. The firm earned “Hold” rating on Tuesday, September 5 by Credit Suisse. The firm has “Outperform” rating by Leerink Swann given on Friday, February 5.

Since August 1, 2017, it had 0 insider purchases, and 11 insider sales for $41.13 million activity. $4.40M worth of Gilead Sciences, Inc. (NASDAQ:GILD) was sold by Washington Robin L on Thursday, September 7. On Tuesday, August 1 the insider Alton Gregg H sold $1.14M. MARTIN JOHN C had sold 73,333 shares worth $6.09M on Thursday, August 31. Meyers James R sold $4.99 million worth of Gilead Sciences, Inc. (NASDAQ:GILD) on Thursday, August 31.

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company has market cap of $97.19 billion. The company??s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It has a 8.47 P/E ratio. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B.

The stock decreased 0.16% or $0.12 during the last trading session, reaching $74.4. About 5.86 million shares traded. Gilead Sciences, Inc. (NASDAQ:GILD) has declined 21.80% since January 9, 2017 and is downtrending. It has underperformed by 38.50% the S&P500.

Among 5 analysts covering Banco Macro SA (NYSE:BMA), 1 have Buy rating, 0 Sell and 4 Hold. Therefore 20% are positive. Banco Macro SA had 7 analyst reports since February 9, 2016 according to SRatingsIntel. The company was upgraded on Monday, September 26 by Goldman Sachs. Goldman Sachs downgraded the shares of BMA in report on Monday, September 11 to “Hold” rating. The rating was initiated by Credit Suisse with “Neutral” on Tuesday, March 29. As per Monday, May 23, the company rating was upgraded by Citigroup. Credit Suisse upgraded the stock to “Buy” rating in Tuesday, June 13 report. The firm has “Neutral” rating given on Wednesday, June 1 by UBS.

Credit Suisse Ag increased D R Horton Inc (NYSE:DHI) stake by 9,407 shares to 720,763 valued at $28.78M in 2017Q3. It also upped Barrick Gold Corp (Call) (NYSE:ABX) stake by 1.23 million shares and now owns 1.68 million shares. Williams Sonoma Inc (NYSE:WSM) was raised too.

Analysts await Banco Macro S.A. (NYSE:BMA) to report earnings on February, 21. They expect $2.69 earnings per share, up 43.09% or $0.81 from last year’s $1.88 per share. BMA’s profit will be $191.50M for 10.51 P/E if the $2.69 EPS becomes a reality. After $2.24 actual earnings per share reported by Banco Macro S.A. for the previous quarter, Wall Street now forecasts 20.09% EPS growth.